Business
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025;
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"image","alt":"Apellis Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Apellis Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":168,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/0911c2871afd8ebcbca1f1edf9bb14b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l.iJQAVIXifrh7qGflOrWg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTY4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0911c2871afd8ebcbca1f1edf9bb14b2","width":168,"height":54}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Full-year 2025 net product revenues of $689 million","length":51,"tagName":"p"}]},{"val":[{"type":"list","items":[{"val":[{"type":"text","content":"SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 million","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"EMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":161,"olType":false}]},{"val":[{"type":"text","content":"Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGF","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitability","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"Management to host conference call today at 8:30 a.m. ET","length":56,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":662,"olType":false},{"type":"text","content":"WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results and business highlights.","length":197,"tagName":"p"},{"type":"text","content":"“2025 was a year of disciplined execution and meaningful progress across the business, and we enter 2026 with clear priorities and a strong foundation,” said Cedric Francois, M.D., Ph.D., chief executive officer at Apellis. “We are focused on positioning SYFOVRE...